Lessons from the mixed-meal tolerance test: Use of 90-minute and fasting C-peptide in pediatric diabetes

Diabetes Care

Volumn 36, Issue 2, 2013, Pages 195-201

  Besser, Rachel E J ^a   Shields, Beverley M ^a   Casas, Rosaura ^b   Hattersley, Andrew T ^a   Ludvigsson, Johnny ^b  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN;

ADOLESCENT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; MIXED MEAL TOLERANCE TEST; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; FASTING; FEMALE; HUMANS; MALE; POSTPRANDIAL PERIOD;

EID: 84873861300     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0836     Document Type: Article

References (34)

1. Greenbaum CJ, Harrison LC; Immunology of Diabetes Society. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 2003; 52:1059-1065
2. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264
3. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al.; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971
4. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
5. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30-36
6. Daneman D, Clarson C. Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control. Clin Invest Med 1987;10:484-487
7. Gjessing HJ, Matzen LE, Frøland A, Faber OK. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics. Diabetes Care 1987;10: 487-490
8. Hendriksen C, Faber OK, Drejer J, Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon. Diabetologia 1977;13:615-619
9. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977;26:605-610
10. Garcia-Webb P, Bonser A, Welborn TA. Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus. Diabetologia 1982;22:296
11. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975;11:541-548
12. Greenbaum CJ, Anderson AM, Dolan LM, et al.; SEARCH Study Group. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009;32:1839-1844
13. Komulainen J, Kulmala P, Savola K, et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 1999;22:1950-1955
14. Mortensen HB, Swift PG, Holl RW, et al.; Hvidoere Study Group on Childhood Diabetes. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoanti-bodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 2010;11:218-226
15. Lazar L, Ofan R, Weintrob N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, doubleblind phase II study. Diabetes Metab Res Rev 2007;23:286-291
16. Raz I, Avron A, Tamir M, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007;23: 292-298
17. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920
18. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-433
19. Bonfanti R, Bazzigaluppi E, Calori G, et al. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 1998;15:844-850
20. Wallensteen M, Dahlquist G, Persson B, et al. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988;31: 664-669
21. Ludvigsson J, Heding LG, Larsson Y, Leander E. C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 1977;66:177-184
22. Greenbaum C, Seidel K, Pihoker C. The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes. Diabetes Care 2004;27:1202-1204
23. Madsbad S, Sauerbrey N, Møller-Jensen B, Krarup T, Kuhl C. Outcome of the glu-cagon test depends upon the prevailing blood glucose concentration in type I (insulin-dependent) diabetic patients. Acta Med Scand 1987;222:71-74
24. Ludvigsson J. Methodological aspects on C-peptide measurements. Acta Med Scand Suppl 1983;671:53-59
25. Gjessing HJ, Reinholdt B, Faber OK, Pedersen O. The effect of acute hyper-glycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1991; 124:556-562
26. Arnold-Larsen S, Madsbad S, Kuhl C. Reproducibility of the glucagon test. Diabet Med 1987;4:299-303
27. Rönnemaa T. Practical aspects in performing the glucagon test in the measurement of C-peptide secretion in diabetic patients. Scand J Clin Lab Invest 1986;46:345-349
28. Mirel RD, Ginsberg-Fellner F, Horwitz DL, Rayfield EJ. C-Peptide reserve in insulin-dependent diabetes. Comparative responses to glucose, glucagon and tol-butamide. Diabetologia 1980;19:183-188
29. Törn C, Landin-Olsson M, Lernmark A, et al. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000;85: 4619-4623
30. Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D. Factors predicting course of beta-cell function in IDDM. Diabetes Care 1992;15:997-1001
31. Knip M, Ilonen J, Mustonen A, Akerblom HK. Evidence of an accelerated B-cell destruction in HLA-Dw3/Dw4 heterozygous children with type 1 (insulin-dependent) diabetes. Diabetologia 1986;29:347-351
32. Decochez K, Keymeulen B, Somers G, et al.; Belgian Diabetes Registry. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care 2000;23:1072-1078
33. Peig M, Gomis R, Ercilla G, Casamitjana R, Bottazzo GF, Pujol-Borrell R. Correlation between residual beta-cell function and islet cell antibodies in newly diagnosed type I diabetes. Follow-up study. Diabetes 1989;38:1396-1401
34. Little RR, Rohlfing CL, Tennill AL, et al. Standardization of C-peptide measurements. Clin Chem 2008;54:1023-1026